These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 28725572)

  • 1. Novel panel of protein biomarkers to predict response to bortezomib-containing induction regimens in multiple myeloma patients.
    Ting KR; Henry M; Meiller J; Larkin A; Clynes M; Meleady P; Bazou D; Dowling P; O'Gorman P
    BBA Clin; 2017 Dec; 8():28-34. PubMed ID: 28725572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Analysis of serum free light chains κ/λ ratio and heavy/light chain pairs of immunoglobulin to the stratification of multiple myeloma according to Mayo Stratification of Myeloma and Revised International Staging System].
    Ščudla V; Balcárková J; Lochman P; Vincová M; Pika T; Minařík J; Zapletalová J; Jarošová M
    Vnitr Lek; 2016 Apr; 62(4):269-80. PubMed ID: 27250604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel panel of protein biomarkers for predicting response to thalidomide-based therapy in newly diagnosed multiple myeloma patients.
    Rajpal R; Dowling P; Meiller J; Clarke C; Murphy WG; O'Connor R; Kell M; Mitsiades C; Richardson P; Anderson KC; Clynes M; O'Gorman P
    Proteomics; 2011 Apr; 11(8):1391-402. PubMed ID: 21365752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Assessment of Heavy/ Light Chain Pairs of Immunoglobulin (Hevylite assay) -  Benefit for Stratification of Multiple Myeloma?].
    Ščudla V; Lochaman P; Pika T; Zapletalová J; Minařík J; Bačovský J
    Klin Onkol; 2015; 28(5):359-69. PubMed ID: 26480864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Further stratification of patients with multiple myeloma by International Staging System in combination with ratio of serum free κ to λ light chains.
    Xu Y; Sui W; Deng S; An G; Wang Y; Xie Z; Yao H; Zhu G; Zou D; Qi J; Hao M; Zhao Y; Wang J; Chen T; Qiu L
    Leuk Lymphoma; 2013 Jan; 54(1):123-32. PubMed ID: 22712834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LDH is an adverse prognostic factor independent of ISS in transplant-eligible myeloma patients receiving bortezomib-based induction regimens.
    Chim CS; Sim J; Tam S; Tse E; Lie AK; Kwong YL
    Eur J Haematol; 2015 Apr; 94(4):330-5. PubMed ID: 25135740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative proteomic profiling of sera from patients with refractory multiple myeloma reveals potential biomarkers predicting response to bortezomib-based therapy.
    Łuczak M; Kubicki T; Rzetelska Z; Szczepaniak T; Przybyłowicz-Chalecka A; Ratajczak B; Czerwińska-Rybak J; Nowicki A; Joks M; Jakubowiak A; Komarnicki M; Dytfeld D
    Pol Arch Intern Med; 2017 Jun; 127(6):392-400. PubMed ID: 28546528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Value of Serum Free Light Chains Measurements in Multiple Myeloma Patients.
    García de Veas Silva JL; Bermudo Guitarte C; Menéndez Valladares P; Rojas Noboa JC; Kestler K; Duro Millán R
    PLoS One; 2016; 11(11):e0166841. PubMed ID: 27893836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Applicability of the International Staging System in Chinese Patients with Multiple Myeloma Receiving Bortezomib or Thalidomide-Based Regimens as Induction Therapy: A Multicenter Analysis.
    Lu J; Lu J; Liu A; Fu W; Du J; Huang X; Chen W; Hou J
    Biomed Res Int; 2015; 2015():856704. PubMed ID: 26640799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of paraprotein gap and β2 microglobulins in predialysis Population with multiple myeloma.
    Ali H; Kishore B; Baharani J
    Saudi J Kidney Dis Transpl; 2019; 30(4):825-831. PubMed ID: 31464239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elucidation of potential bortezomib response markers in mutliple myeloma patients.
    Hsieh FY; Tengstrand E; Pekol TM; Guerciolini R; Miwa G
    J Pharm Biomed Anal; 2009 Jan; 49(1):115-22. PubMed ID: 19062221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple myeloma staging based on the combination of beta-2-microglobulin and albumin: the role of albumin in the model.
    Mihou D; Katodritou E; Zervas K
    Hematology; 2007 Dec; 12(6):527-31. PubMed ID: 17852450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship of differences in immunoglobulin heavy/light chain pairs (Hevylite), selected laboratory parameters and stratification systems in different immunochemical types of multiple myeloma.
    Scudla V; Lochman P; Pika T; Minarik J; Zapletalova J; Bacovsky J
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2016 Mar; 160(1):84-93. PubMed ID: 26365929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of novel biomarkers in plasma for prediction of treatment response in patients with heart failure.
    Cao TH; Quinn PA; Sandhu JK; Voors AA; Lang CC; Parry HM; Mohan M; Jones DJ; Ng LL
    Lancet; 2015 Feb; 385 Suppl 1():S26. PubMed ID: 26312848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid progression of anemia related to tumor-lysis syndrome associated with bortezomib treatment in myeloma patients.
    Suzuki K; Terui Y; Nishimura N; Ueda K; Mishima Y; Sakajiri S; Yokoyama M; Aiba K; Hatake K
    Jpn J Clin Oncol; 2014 May; 44(5):435-41. PubMed ID: 24664944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and confirmation of a protein biomarker panel with potential to predict response to biological therapy in psoriatic arthritis.
    Ademowo OS; Hernandez B; Collins E; Rooney C; Fearon U; van Kuijk AW; Tak PP; Gerlag DM; FitzGerald O; Pennington SR
    Ann Rheum Dis; 2016 Jan; 75(1):234-41. PubMed ID: 25187158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High chymotrypsin-like activity in the plasma of patients with newly diagnosed multiple myeloma treated with bortezomib is predictive of a better response and longer PFS.
    Romaniuk W; Bolkun L; Kalita J; Galar M; Bernatowicz M; Ostrowska H; Kloczko J
    Ann Hematol; 2018 Oct; 97(10):1879-1887. PubMed ID: 29946907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
    Durie BGM; Hoering A; Abidi MH; Rajkumar SV; Epstein J; Kahanic SP; Thakuri M; Reu F; Reynolds CM; Sexton R; Orlowski RZ; Barlogie B; Dispenzieri A
    Lancet; 2017 Feb; 389(10068):519-527. PubMed ID: 28017406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Retrospective study comparing low-dose versus standard dose of bortezomib in patients with multiple myeloma].
    Espinoza Zelada M; Befferman Cordova N; Ocqueteau Tachini M; Ramírez Villanueva P; Galleguillos M M; Sarmiento Maldonado M
    Medwave; 2015 Mar; 15(2):e6098. PubMed ID: 25831273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.